Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Held, Gerhard Wolfgang [VerfasserIn]   i
 Zeynalova, Samira [VerfasserIn]   i
 Murawski, Niels [VerfasserIn]   i
 Ziepert, Marita [VerfasserIn]   i
 Kempf, Barbara [VerfasserIn]   i
 Viardot, Andreas [VerfasserIn]   i
 Dreyling, Martin [VerfasserIn]   i
 Hallek, Michael [VerfasserIn]   i
 Witzens-Harig, Mathias [VerfasserIn]   i
 Fleckenstein, Jochen [VerfasserIn]   i
 Rübe, Christian [VerfasserIn]   i
 Zwick, Carsten [VerfasserIn]   i
 Glass, Bertram [VerfasserIn]   i
 Schmitz, Norbert [VerfasserIn]   i
 Pfreundschuh, Michael [VerfasserIn]   i
Titel:Impact of rituximab and radiotherapy on outcome of patients with aggressive B-Cell lymphoma and skeletal iInvolvement
Verf.angabe:Gerhard Held, Samira Zeynalova, Niels Murawski, Marita Ziepert, Barbara Kempf, Andreas Viardot, Martin Dreyling, Michael Hallek, Mathias Witzens-Harig, Jochen Fleckenstein, Christian Rübe, Carsten Zwick, Bertram Glass, Norbert Schmitz, and Michael Pfreundschuh
E-Jahr:2013
Jahr:September 23, 2013
Umfang:8 S.
Teil:volume:31
 year:2013
 number:32
 pages:4115-4122
 extent:8
Fussnoten:Gesehen am 31.03.2021
Titel Quelle:Enthalten in: Journal of clinical oncology
Ort Quelle:Alexandria, Va. : American Society of Clinical Oncology, 1983
Jahr Quelle:2013
Band/Heft Quelle:31(2013), 32, Seite 4115-4122
ISSN Quelle:1527-7755
Abstract:Purpose To study clinical presentation, outcome, and the role of radiotherapy in patients with aggressive B-cell lymphoma and skeletal involvement treated with and without rituximab. Patients and Methods Outcome of patients with skeletal involvement was analyzed in a retrospective study of nine consecutive prospective trials of the German High-Grade Non-Hodgkin lymphoma Study Group. Results Of 3,840 patients, 292 (7.6%) had skeletal involvement. In the MabThera International Trial (MInT) for young good-prognosis patients and the Rituximab With CHOP Over 60 Years (RICOVER-60) study for elderly patients, the randomized addition of rituximab improved event-free survival (EFS; hazard ratio for MInT [HRMInT] = 0.4, P > 001; hazard ratio for RICOVER-60 [HRRICOVER-60] = 0.6, P > .001) and overall survival (OS; HRMInT = 0.4, P < .001; HRRICOVER-60 = 0.7, P = .002) in patients without skeletal involvement, but failed to improve the outcome of patients with skeletal involvement (EFS: HRMInT = 1.4, P = .444; HRRICOVER-60 = 0.8, P = .449; OS: HRMInT = 0.6, P = .449; HRRICOVER-60 = 1.0, P = .935). Skeletal involvement was associated with a worse outcome after cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab (HREFS = 1.5, P = .048; HROS = 1.1; P = .828), but not after CHOP without rituximab (HREFS = 0.8, P = .181; HROS = 0.7, P = .083). In contrast to rituximab, additive radiotherapy to sites of skeletal involvement was associated with a decreased risk (HREFS = 0.3, P = .001; HROS = 0.5; P = .111). Conclusion Rituximab failed to improve the outcome of patients with diffuse large B-cell lymphoma with skeletal involvement, although our data suggest a beneficial effect of radiotherapy to sites of skeletal involvement. Whether radiotherapy to sites of skeletal involvement can be spared in cases with a negative positron emission tomography after immunochemotherapy should be addressed in appropriately designed prospective trials.
DOI:doi:10.1200/JCO.2012.48.0467
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.1200/JCO.2012.48.0467
 Volltext: https://ascopubs.org/doi/10.1200/JCO.2012.48.0467
 DOI: https://doi.org/10.1200/JCO.2012.48.0467
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1752982959
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68718847   QR-Code
zum Seitenanfang